Avana, also known by its generic name avanafil, is a phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED) in men. The mechanism of action of Avana involves its ability to inhibit the enzyme PDE5, which plays a role in regulating blood flow in the penis. Here's a breakdown of its mechanism:
- PDE5 Inhibition:
- Avana belongs to the class of medications known as PDE5 inhibitors. PDE5 is an enzyme present in the smooth muscle cells of the penis.
- Inhibition of PDE5 results in increased levels of cyclic guanosine monophosphate (cGMP), a chemical messenger that promotes relaxation of smooth muscle cells in the penile arteries and corpus cavernosum (a spongy tissue in the penis).
- Relaxation of Smooth Muscles:
- As cGMP levels increase, smooth muscles in the penile blood vessels relax.
- This relaxation allows for increased blood flow to the penis during sexual stimulation, leading to engorgement of the corpus cavernosum and the development of an erection.
- Enhanced Erection:
- The increased blood flow and improved circulation in response to sexual stimulation contribute to the achievement and maintenance of an erection.
- Avana does not cause spontaneous erections; sexual arousal and stimulation are still necessary for the medication to be effective.
- Rapid Onset of Action:
- Avana is known for its relatively rapid onset of action, with effects occurring as early as 15-30 minutes after administration.
- This quick onset makes it suitable for on-demand use, allowing flexibility in timing sexual activity.